NCT07195994招募中不适用
A Randomized, Single-blind, Controlled, Parallel Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes
QuickSilver Scientific1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2026年2月5日最近更新:
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- The difference in change in fasting blood glucose between AMPK Charge+® and AMPK Charge+® with semaglutide
研究概览
简要总结
This is a randomized, single-blind, controlled, parallel clinical trial to examine the efficacy and safety of AMPK Charge+® with and without use of semaglutide on glycemic response in adults with prediabetes or Type 2 Diabetes. The main question it aims to answer is:
What is the difference in change in fasting blood glucose and insulin, and hemoglobin A1c (HbA1c) from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide?
Participants will consume AMPK Charge+® with or without semaglutide injections and will be evaluated for glycemic response parameters.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
盲法说明
This is a single-blind clinical trial wherein the Statistician and Research Scientist will be blinded to the allocation of study arms.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males & females between 18 years of age or older
- •Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening
- •Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
- •Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
- •Double-barrier method
- •Intrauterine devices
- •Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)
- •Vasectomy of partner at least 6 months prior to screening
- •Abstinence and agrees to use contraception if becomes sexually active during this study
- •Individuals eligible for, but not currently taking, semaglutide therapy as per standard-of-care including adults with:
- •Prediabetes (HbA1c 6.0-6.5%) who are treatment naïve
- •Type 2 Diabetes (HbA1c 6.5-7.5%) who are treatment naïve and metformin is inappropriate due to contraindication or intolerance
- •Self-reported stable body weight defined as not having gained or lost more than 5 kg of body weight in the three months prior to baseline
- •Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, sleep, use of nicotine, tobacco and cannabinoid products) as much as possible throughout the study
- •Willingness to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits
- •Provided voluntary, written, informed consent to participate in the study
排除标准
- •Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
- •Allergy, sensitivity, intolerance, or dietary restriction preventing use of study products
- •Personal or family history of MTC or in patients with MEN 2
- •Unstable metabolic disease or chronic diseases as assessed by the QI
- •Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI
- •Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI (See Section 7.3)
- •Type I diabetes or diabetic ketoacidosis
- •Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis
- •History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months
- •Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
- •Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI
- •Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable
- •Individuals with an autoimmune disease or are immune compromised
- •Self-reported confirmation of a HIV-, Hepatitis B- and/or C-positive diagnosis as assessed by the QI
- •Self-reported confirmation of blood/bleeding disorders as assessed by the QI
- •Alcohol intake average of >2 standard drinks per day as assessed by the QI
- •Alcohol or drug abuse within the last 12 months
- •Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the efficacy and/or safety of the study products (See Section 7.3)
- •Clinically significant abnormal laboratory results at screening as assessed by the QI
- •Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit
- •Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI
- •Individuals who are unable to give informed consent
- •Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
研究组 & 干预措施
AMPK Charge+®
Experimental
AMPK Charge+® is a dietary supplement comprised of highly purified phospholipids, diindolylmethane, quercetin dihydrate, milk thistle seed extract, resveratrol, and berberine delivered using liposomal and nanoemulsion technology.
干预措施: AMPK Charge+® (Dietary Supplement)
AMPK Charge+® with semaglutide
Active Comparator
Subcutaneous semaglutide (Ozempic®), a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for adults with T2D to improve glycemic control with the safety and efficacy extensively investigated leading to approvals by the United States (U.S.) Food and Drug Administration and Health Canada
干预措施: AMPK Charge+® with semaglutide (Dietary Supplement)
结局指标
主要结局
The difference in change in fasting blood glucose between AMPK Charge+® and AMPK Charge+® with semaglutide
时间窗: Day 0 to 84
The difference in change in fasting blood glucose from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide
The difference in change in fasting insulin between AMPK Charge+® and AMPK Charge+® with semaglutide
时间窗: Day 0 to 84
The difference in change in fasting insulin from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide
The difference in change in hemoglobin A1c (HbA1c) between AMPK Charge+® and AMPK Charge+® with semaglutide
时间窗: Day 0 to 84
The difference in change in hemoglobin A1c (HbA1c) from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide
次要结局
- The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in fasting blood glucose(Day 0 to 42)
- The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in HbA1c(Day 0 to 42)
- The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in fasting insulin(Day 0 to 42)
- The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in High-Density Lipoprotein (HDL) cholesterol(Day 0 to 84)
- The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in , High-Density Lipoprotein (HDL) cholesterol(Day 0 to 42)
- The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Triglycerides (TG),(Day 0 to 42)
- The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in TC:HDL-C, TG:HDL-C, and LDL-C:HDL-C ratios(Day 0 to 42)
- The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Apolipoprotein B100 (ApoB100)(Day 0 to 84)
- The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in e. Body weight(Day 0 to 42)
- The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Inflammatory markers as assessed by C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)(Day 0 to 42)
- The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in f. Framingham 10-year cardiovascular risk score (FCVRS)(Day 0 to 42)
- The difference in change from baseline at Day 84 between AMPK Charge+® and AMPK Charge+® with semaglutide in Postprandial glucose and insulin as assessed by an oral glucose tolerance test (OGTT)(Day 0 to 84)
- The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)(Day 0 to 42)
- The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)(Day 0 to 84)
- The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Triglycerides (TG),(Day 0 to 84)
- The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in TC:HDL-C, TG:HDL-C, and LDL-C:HDL-C ratios(Day 0 to 84)
- The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in Inflammatory markers as assessed by C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)(Day 0 to 84)
- The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in e. Body weight(Day 0 to 84)
- The difference in change between AMPK Charge+® and AMPK Charge+® with semaglutide in f. Framingham 10-year cardiovascular risk score (FCVRS)(Day 0 to 84)
研究者
研究点 (1)
Loading locations...
相似试验
未知
4 期
A clinical trial to determine whether local application of autologous bone marrow injections can help in healing chronic woundsCTRI/2009/091/000250Christian Medical College, Vellore, Tamil Nadu, India60
已完成
4 期
Study to Investigate if Adding Lactulose to Vitamin D and Calcium Has an Effect on the Preservation of Bone in Postmenopausal WomenOsteopeniaNCT00160264Solvay Pharmaceuticals40
已完成
3 期
Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial InfarctionNCT07146360AO GENERIUM180
招募中
2 期
A study on the effect of Shatavari Siddha Ghrita eye drops in treating Dry Eye Syndrome.CTRI/2025/04/085498Dr Niranjan Ulhas Shinde70
未知
2/3 期
A clinical trial to study the efficacy of probiotic Lactobacillus brevis lozenges in patients with chronic periodontitisCTRI/2009/091/000006CD Pharma India Pvt. Ltd. C 1/53, Ist floor, SDA, New Delhi-110016, Tel.01141759898, Fax. 0114175989150